Highlights:
- A closer look at the latest clinical data regarding flow diversion technologies – including new insights on the Flow redirection endoluminal device (FRED; MicroVention/Terumo) and five-year results from the SCENT trial (Stryker Neurovascular)
- The unique ethical considerations created by an emergence of remote stroke interventions
- The “new world” that Synchron’s brain-computer interface technology, the Stentrode device, could open up in neurovascular therapy
- Profile: Else Charlotte Sandset (Oslo, Norway)
- Neuromodulation: a special edition dedicated to the most significant research and innovations seen in the spinal cord stimulation (SCS) field recently
